The primary endpoint of the study was to assess if the change from baseline in HbA1c achieved with ONGLYZA 5 mg per day was non-inferior (defined in the study protocol as a treatment group numerical ...

WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA(TM) (sitagliptin), the only DPP-4 inhibitor ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

Today, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analogue, Victoza® (liraglutide) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that ...

COPENHAGEN, June 26 (Reuters) - Novo Nordisk said on Saturday extension data from a study showed its new diabetes drug Victoza provided better blood sugar control and also weight reduction than ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin ...

Danish Novo Nordisk, the world's biggest insulin producer, said on Friday it had received a product label update for diabetes drug Victoza to include data showing superior efficacy when compared with ...

In terms of controlling Type 2 diabetes and potentially obesity, Boston’s Intarcia Therapeutics just released some impressive Phase 3 findings: Its implantable device has been found to be more ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of ...